05/09/23 4:01 PMNasdaq : MGNX earningsMacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial ResultsZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipeline Multiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC) Cash runway through 2025 with $270 million in non-dilutive funding achieved over past nine months Conference callRHEA-AIneutral
05/04/23 4:30 PMNasdaq : MGNX earningsMacroGenics Announces Date of First Quarter 2023 Financial Results Conference CallMacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financialRHEA-AIneutral
04/24/23 6:15 PMNasdaq : MGNX conferencesMacroGenics to Participate in Upcoming Investor ConferencesMacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in theRHEA-AIneutral
03/22/23 1:22 PMNasdaq : MGNX fda approvalMacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administration’sRHEA-AIvery positive
03/15/23 4:01 PMNasdaq : MGNX earningsMacroGenics Provides Corporate Update and 2022 Financial ResultsCash runway extended through 2025 with $ 250 million in non-dilutive funding over past eight months TAMARACK study design modified with objective of accelerating data readout Encouraging lorigerlimab (PD-1 × CTLA-4 bispecific DART ® molecule) monotherapy clinical data presented at ASCO-GURHEA-AIpositive
03/14/23 8:14 AMNasdaq : MGNX Synaffix Announces Expansion of ADC Collaboration with MacroGenicsSynaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index, has announced the expansion of its license agreement with MacroGenics Inc., a biopharmaceutical company focused on developing and commercializing...RHEA-AIpositive
03/08/23 5:36 PMNasdaq : MGNX MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has entered into an agreement to sellRHEA-AIneutral
03/07/23 6:00 PMNasdaq : MGNX earningsMacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference CallMacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financialRHEA-AIneutral
03/02/23 4:30 PMNasdaq : MGNX conferencesMacroGenics to Participate in Upcoming Investor ConferencesMacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in theRHEA-AIneutral
02/13/23 5:20 PMNasdaq : MGNX clinical trialMacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers SymposiumTwelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90% PSA reduction (PSA90) Nine of 35 patients (25.7%) with measurable mCRPC achieved confirmed partialRHEA-AIneutral